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Abstract 
 
Psychotic patients with a lifetime history of cannabis use generally show better cognitive 
functioning than other psychotic patients. Some authors suggest that cannabis-using patients may 
have been less cognitively impaired and less socially withdrawn in their premorbid life.  
Using a dataset comprising 948 patients with first-episode psychosis (FEP) and 1313 population 
controls across six countries, we examined the extent to which IQ and both early academic (AF) and 
social adjustment (SF) are related to the lifetime frequency of cannabis use in both patients and 
controls. We expected a higher IQ and a better premorbid social adjustment in psychotic patients who 
had ever used cannabis compared to patients without any history of use. We did not expect such 
differences in controls. 
In both patients and controls, IQ was three points higher among occasional-users than in never-
users [mean difference (Mdiff)=2.9, 95% C.I.=(1.2, 4.7)]. Both cases and control daily-users had lower 
AF compared to occasional [Mdiff=-0.3, 95% C.I.=(-0.5; -0.2)] and never-users [Mdiff=-0.4, 95% 
C.I.=(-0.6; -0.2)]. Finally, patient occasional [Mdiff=0.3, 95% C.I.=(0.1; 0.5)] and daily-users 
[Mdiff=0.4, 95% C.I.=(0.2; 0.6)] had better SF than their never-using counterparts. This difference 
was not present in controls (Fgroup*frequency(2, 2.205)=4.995, p=0.007).  
Our findings suggest that the better premorbid social functioning of FEP with a history of cannabis 
use may have contributed to their likelihood to begin using cannabis, exposing them to its reported 
risk-increasing effects for Psychotic Disorders.  
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1. Introduction  
Cannabis use is well established as a risk factor for psychosis1–3. While cannabis is known to have 
an acute adverse effect on cognition in healthy subjects4,5, paradoxically, patients with psychotic 
disorders who report lifetime cannabis use, but not current use6, appear to have better cognitive 
performance than patients who do not7–9.  
Many, but not all, people with a diagnosis of psychosis show subtle cognitive and social 
impairments before the emergence of prodromal symptoms10–12 and some authors suggest that 
cannabis-using patients may constitute a phenotypically distinct group, with different neurological, 
cognitive, clinical and prognostic characteristics13. One explanation of the counterintuitive cognitive 
findings concerning cannabis is that those psychotic patients who use cannabis had better premorbid 
cognitive function than those who have not. 
In the GAP (Genetic and Psychotic Disorder) study14, we found that first episode psychotic 
patients (FEP) with a history of cannabis use at any time in their life, had a higher premorbid IQ 
compared to other FEP patients, a difference not witnessed among controls. We proposed that 
cannabis use increases the risk of psychosis in a subgroup of patients with less neurodevelopmental 
vulnerability to the disease7,14–19.  
It has been suggested that good premorbid social functioning is crucial to develop and sustain an 
illegal drug habit20–22. However, there are few studies on the relationship between cannabis use and 
neurocognitive functioning in psychosis that controlled for premorbid functioning. One study on 104 
FEP22 reported higher premorbid sociability, but not differences in premorbid IQ, in those with 
cannabis use before the onset compared to those without any use. Two other studies23,24 have shown 
that FEP with a history of cannabis use23 or cannabis use disorder24 have a better premorbid social 
adjustment but poorer premorbid academic adjustment and less educational attainment compared to 
other patients with no such history. Nonetheless, neither of these two studies had data on IQ. 
Longitudinal studies on non-psychotic subjects consistently showed a relationship between higher  
IQ in childhood and occasional or discontinued cannabis-use (but not to habitual use which was 
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linked to lower or equal IQ, compared with non-use) probably due to the tendency of those with 
higher IQ to experiment with drugs25–31.  
Using data from the EUropean network of national schizophrenia networks studying Gene-
Environment Interactions (EU-GEI) study, we set out to examine the association between current IQ, 
premorbid social and academic adjustment and lifetime frequency of cannabis use in patients with a 
first episode psychotic disorder (FEP) and a sample of population controls.  
We expected a higher IQ and a better social premorbid adjustment in psychotic patients who had 
ever used cannabis compared to patients without any history of use. We did not expect such 
differences in controls. 
 
 
2. Methods  
 
2.1. Study Design 
Data were derived from The European Network of National Schizophrenia Networks Studying 
Gene-Environment Interactions (EU-GEI) study (http://www.eu-gei.eu)32,33. Subjects were identified 
between 01/05/2010 and 01/04/2015 across centres in five different European countries and Brazil to 
examine incidence rates of psychotic disorders. We performed an extensive assessment of 
approximately 1000 FEP patients and 1000 population-based controls during the same period to 
investigate risk factors for psychosis.  
 
2.2. Subjects  
Patients: Screening was run by skilled researchers on all potential FEP patients at their first contact 
with the mental health services and residents in each catchment area, who were aged 18-64 years and 
received a diagnosis of psychoses (ICD-10: F20-F33)34 in the study period. We excluded those with 
psychotic symptoms precipitated by acute intoxication (ICD10: F1X.5), or psychosis due to another 
medical condition (ICD10: F09), and those who had previously received antipsychotic medication.  
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Controls: Population-based volunteers aged 18 to 64 years, who had never received treatment for 
psychosis, representative of each local population, were recruited through a mixture of random and 
quota sampling (population stratification by age, gender and ethnicity)33,35. All the study sites 
received approval from their local ethical committees. All subjects signed a written consent form and 
data was stored anonymously32. 
 
2.3. Measures 
We used the modified version of the Medical Research Council (MRC) socio-demographic scale36. 
Diagnoses, first ascertained by clinical interview, were operationalised through the 90-item 
computerised OPCRIT system for psychosis37,38. The Cannabis Experience Questionnaire, further 
modified for the EUGEI study (CEQEU-GEI)
35, included a section from Composite International 
Diagnostic Interview (CIDI) on other substances of abuse, and tobacco use in the last 12 months39. 
An abbreviated version of the WAIS was used in patients and controls in order to estimate full 
scale-IQ scores40. Given the multi-site design, we could not use a psychometric test to assess 
premorbid IQ, but only performed an exploratory supplementary analysis on the WAIS subtests, to 
examine the relation with cannabis use of  the “hold” intellectual capacities41. To assess premorbid 
adjustment, we used nine scales from the Premorbid Adjustment Scale (PAS) 42,43 to examine in 
patients and controls “the degree of achievement of developmental goals” 44–46, in two distinct 
developmental age-periods: childhood to age 11 and early adolescence (i.e. 12 to age 16), so that all 
patients could score the same scales, regardless of their age-of-onset47,48 (further details on measures 
are in the Supplementary Material). 
 
2.4. Statistical Analysis 
In the patient/control comparisons, we used either t-test or ANCOVA and Welch test for 
continuous variables and the Chi-square tests, for categorical variables, with adjusted ORs and 95% 
C.I.s for cannabis variables. Confounders were selected if they resulted associated with both 
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patient/control status and the outcomes. Cannabis and premorbid variables were adjusted for gender, 
age, ethnicity and country. IQ was further corrected by education.  
The frequency of cannabis-use in the lifetime was reduced to three categories by adjusted logistic 
regression and codified as never use=0; occasional use=1; daily use=2. Daily use was conservatively 
chosen as the highest category. Never use was separated a priori as the baseline category, for 
theoretical reasons. Occasional-users were people who used cannabis up to “more than once a week” 
(Supplementary Material, Supplementary-Table 1).  
We calculated a reverse-score and extracted two factors from the Premorbid Adjustment Scale 
(PAS), namely the Social Factor (SF) and the Academic Factor (AF), obtained by a principal-
component analysis (PCA), which explained the 64.4% of the variance (Supplementary Material). 
In order to establish differences in SF, AF and IQ (i.e. the outcomes) related to frequency of 
cannabis use and patient/control group as fixed factors, we performed a MANCOVA which allowed 
us to take into account the correlation among these dependent variables. In the case of asymmetric 
distributions of the outcomes, bias-corrected and accelerated (BCa) 95% confidence intervals (C.I.s) 
were calculated, using 1000 Bootstrap samples49. Box’s M was used to test the covariance matrix. 
Pillai's trace statistics tested statistical significance. Bonferroni multiplicity correction for multiple 
comparisons was applied. Interactions were explored in a follow-up ANCOVA for each dependent 
variable.  
One hypothesised mechanism involving cannabis in risk of psychosis implicates dopaminergic 
disregulation50, similarly to other drugs’, such as stimulants51 and tobacco52. Additionally, current 
cannabis use53 is associated with worse cognitive performance, and the effect of nicotine on 
neurocognition is still controversial in schizophrenia54,55. Therefore, to ensure that the results were 
not biased, we ran sensitivity analyses by eliminating from the sample, alternatively and then 
simultaneously in any combination, all subjects (i) who used cannabis in the last twelve months (i.e. 
current cannabis users), (ii) who used tobacco in the last twelve months (i.e. current tobacco users), 
and (iii) who abused at least one illegal drug, other than cannabis, in their lifetime (i.e. lifetime other 
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drug-abusers). Figures were obtained by transforming the outcome variables into standardised scores. 
To account for symptomatology, which could confound results in IQ, we wanted to exploratory 
correct the primary analysis, by including the patients’ group only, for the negative symptoms 
dimension score extracted from the OPRCIT56. 
We used an inverse probability weight, calculated on key demographics such as age, gender and 
ethnicity, to account for controls’ under- or oversampling35 and this weight was applied to all the 
analyses (Supplementary Material). All statistical analyses were conducted using SPSS 25. 
 
3. Results 
3.1. Descriptive Characteristics  
The sample studied comprised those 2.261 subjects (948 patients and 1.313 controls) from the 
original sample who completed at least the CEQEU-GEI and the PAS instrument (Supplementary-
Figure 1; Supplementary-Table 2). Patients were more often men [61.9% (587) vs 47.6% (625); 
χ2(1)=45.3] and younger than controls [mean age= 30 (10.4) vs 36.1 (13); t(2.257)=-10.9]. Controls 
were more likely to be of white ethnicity [77.3% (1.015) vs 63.2% (599); χ2(2)=54.8] and to have 
achieved a university degree [38.8% (508) vs 16% (151); χ2(3)=222.7] than patients. Patients were 
more often unemployed at the time of the interview [73.8% (962) vs 42.4% (394); χ2(1)=225.2]; they 
were also more likely to be single [64.1% (605) vs 30.5% (399); χ2(2)=272.6] or living with their 
parents [57.5% (539) vs 27.1% (353); χ2(2)=252.9] (all p<0.001) (Supplementary-Table 3). 
 
3.2. Cannabis Use 
Patients were almost twice as likely to have used cannabis in their lifetime [OR=1.71 95% 
C.I.=(1.41; 2.07)], to have chosen high potency cannabis [OR=1.73, 95% C.I.=(1.31; 2.27)] (i.e. total 
levels of THC≥10%) and to currently use cannabis [OR=1.61, 95% C.I.=(1.26; 2.06)]; patients were 
also five times more likely to have used cannabis on a daily basis [OR=5.0, 95% C.I.=(3.75; 6.69)], 
compared to controls. 77.3% (464) of patients and 84.9% (535) of controls [χ2(1)=11.5, p=0.001] 
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who had ever used cannabis declared they started smoking cannabis socially, i.e. because their friends 
were using it. However, patients mostly used cannabis in solitude at the time of the interview 
compared to controls [OR=3.78, 95% C.I.=(2.69; 5.32)]. Finally, patients were more than three times 
more likely to be current tobacco-users (OR=3.47, 95% C.I.=[2.88; 4.19]) and to have abused other 
drugs in their lifetime (OR=3.43, 95% C.I.=[2.35; 4.99]) (Supplementary-Table 4).  
 
3.3. Clinical Characteristics 
Compared to controls, patients had lower IQ [mean difference (Mdiff)=-17.3, 95% C.I.=(-18.6; -
15.40)], lower SF [Mdiff -0.4, 95% C.I.=(-0.5; -0.3)], and AF scores [Mdiff=-0.5, 95% C.I.=(-0.6; -
0.4)] (Table 1).  
The outcomes (SF, AF and IQ) were weakly skewed (SF=-0.68; AF=-0.97; IQ=0.13). SF and AF 
were related to IQ (Spearman’s Rho: IQ*AF=0.439, p<0.001; IQ*SF=0.049, p<0.026).  
 
3.4. IQ and Premorbid Adjustment by Frequency of Cannabis Use in Patients and Controls 
There was a significant effect of patient/control status [Pillai=0.15, F(1, 2.040)=122.8; p<0.001], 
frequency of cannabis use [Pillai=0.03 F(2, 2.040)=13.6, p<0.001], country [Pillai=0.16, F(5, 
2.040)=23, p<0.001], gender [Pillai=0.04, F(1, 2.040)=30.8, p<0.001], age [Pillai=0.008, F(1, 
2.040)=5.5, p=0.001], and ethnicity [Pillai=0.11; F(2, 2.040)=42.8, p<0.001] on IQ, SF and AF scores 
(Table 2). The association between the three outcomes and frequency of cannabis use was different 
in patients and controls [Pillaigroup*frequency=0.006, F(2, 2.040)=2.17, p=0.042]. Follow up analysis 
revealed that frequency of use had a similar effect on the IQ of patients and controls [Fgroup*frequency(2, 
2.062)=0.45, p=0.635]. Overall, occasional-users had three points higher IQ, compared to never-users 
[Mdiff=2.9, 95% C.I.=(1.2, 4.7)], but there were no differences between daily-users and both 
occasional [Mdiff=-2.1, 95% C.I.=(-4.6, 0.3)] and never-users [Mdiff=0.8, 95% C.I.=(-1.7, 3.3)]. 
On the other hand, patients and controls who were daily cannabis-users were very similar to each 
other regarding AF [Mdiff=-0.2, 95% C.I.=(-0.6; 0.003)] and they both had lower scores, as compared 
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to their respective occasional [Mdiff=-0.3, 95% C.I.=(-0.5; -0.2)] and never-using counterparts [Mdiff=-
0.4, 95% C.I.=(-0.6; -0.2)] [Fgroup*frequency(2, 2.205)=1.22, p=0.295].    
Regarding SF, we found a significant interaction effect [Fgroup*frequency(2, 2.205)=4.99, p=0.007]: 
SF was better in patients who were occasional [Mdiff=0.3, 95% C.I.=(0.1; 0.5)] or daily-users 
[Mdiff=0.4, 95% C.I.=(0.2; 0.6)], compared to never-user patients, while there was no effect of 
cannabis use on SF in controls (Table 2, Figure 1).  
The results concerning the patient group stayed consistent once corrected for negative symptoms 
(Pillaifrequency=0.052, F(6, 1.542)=6.84, p<0.001) (Supplementary-Table 5).  
 
3.5 Sensitivity-analysis 
We identified (i) 209 FEP and 146 controls who were current cannabis-users; (ii) 515 FEP and 
311 controls who were current tobacco-users; (iii) 120 FEP and 37 controls who were lifetime other 
drug-abusers (Supplemetary-Table 2). When these subjects were removed, in any combination, the 
results were consistent with the primary analysis. The most interesting result was revealed when all 
previous categories were simultaneously removed. This final sample comprised 382 patients and 921 
controls. We found a significant interaction effect on IQ [Fgroup*frequency(2, 1.208)=4.42, p=0.012]. 
Patients who were occasional-users (N=97; mean IQ=87.6, SE=1.8) had eight points higher IQ 
[Mdiff=8.3, 95% C.I.=(4.2; 12.7)] than never-user patients (N=249; mean IQ=79.3, SE=1.1), while in 
controls we only found a three points difference [Mdiff=2.8, 95% C.I.=(0.07; 5.6)] between occasional 
(N=302, mean IQ=98.7, SD=1.1) and never-users (N=584; mean= 95.8, SE=0.8).  
In line with the original analysis, AF was similarly related to cannabis use in patients and in 
controls [Fgroup*frequency(2, 1.272)=0.93, p=0.392]. Both patients and control daily-users had lower 
scores than never- [Mdiff=-0.5, 95% C.I.=(-0.8; -0.2)] and occasional-users [Mdiff=-0.5, 95% C.I.=(-
0.8; -0.1)], but difference with occasional-users was more significant for controls (Table 3).  
Regarding SF, we replicated the interaction effect of frequency of cannabis use in patients, but not 
in controls [Fgroup*frequency(2, 1.272)=6.75, p=0.001]: patients who were occasional [Mdiff=0.2, 95% 
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C.I.=(0.006; 0.5)] or daily-users [Mdiff=0.7, 95% C.I.=(0.3; 1.1)] had higher scores than never-user 
patients, and daily-users scored better than occasional-users [Mdiff=0.4, 95% C.I.=(0.05; 0.8)]. 
Furthermore, patients who were daily-users had 1) similar IQ (Mdiff=-5.5, 95% C.I.=[-17.1, 4.2]) and 
AF (Mdiff=-0.07, 95% C.I.=[-0.6; 0.4]) compared to daily-user controls; and 2) they had very similar 
or even better mean scores of SF (mean=0.2, 95% C.I.=[-0.1; 0.5]) than control daily- (mean=0.3, 
95% C.I.=[0.03; 0.5]), occasional (mean=0.2, 95% C.I.=[0.1; 0.3]), and never-users (mean=0.1, 95% 
C.I.=[0.07; 0.2]) (Table 3, Figure 2). 
 
4. Discussion 
 
4.1 Summary of main results 
Our first main finding indicated higher IQ in the cannabis occasional-using subgroup of patients 
compared with their never-user counterparts, and a similar effect in controls. Early academic 
adjustment (AF) was lower when the frequency of cannabis use increased in both patients and 
controls. Finally, patients with a history of occasional or daily cannabis use had been less socially 
withdrawn (i.e. had higher SF scores) compared to those psychotic patients who never used cannabis, 
a difference that was not seen within controls.  
 
4.2 Comparison with previous literature 
All differences between patients and controls, in terms of socio-demographics57–59, IQ60–62 and 
premorbid conditions63,64 were expected as the control group was selected to be representative of the 
general population of each area and not to be matched with the case group. We also confirmed the 
expected differences between patients and controls in patterns of cannabis use24,35,65–67. 
Regarding IQ, we confirmed that cannabis-using patients have higher IQ than never-users and 
showed that this effect is attributable to occasional cannabis-users, who represent the biggest 
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proportion of users68. In contrast to previous research with a similar design69, our results remained 
consistent after controlling for several confounders and the sensitivity analysis revealed an IQ more 
than eight points higher in occasional-using patients than in never-users, a much greater effect than 
the three-points difference detected among controls (see also70,71). To date, this is the first study that 
a) included a control group in exploring this effect and b) found a higher IQ in cannabis occasional-
using population controls. These findings differ from the Dunedin study, which identified an IQ 
decline in cannabis-users but this latter was over several decades of adult life72. Nevertheless, in the 
Dunedin study, those who reported lifetime use of cannabis, but not dependence, were cognitively 
spared, while in currently dependent people cognition declined72. The descriptive differences we 
found between daily- and occasional-user controls indicate a higher academic achievement and a later 
contact with the substance in the latter, which could have prevented them from dependence and 
related academic failure, thus influencing future IQ. However, education was not sufficient to account 
for the differences in IQ according to frequency of cannabis use in our analysis, when it was inserted 
to adjust comparisons. This is not surprising, as we know that IQ scores are multi-determined and 
partially hereditary73, and therefore probably differently related to premorbid IQ accordingly to 
patterns of cannabis use, as suggested in longitudinal studies of non-psychotic subjects25–31. 
Additionally, there are recent suggestions that IQ in psychosis is associated with the polygenic risk 
score (PRS) that indexes cognition in the general population and is partly independent from PRS 
predisposing to schizophrenia74; this could corroborate our finding of a similar relationship of IQ with 
cannabis use in patients and controls. 
Those patients and controls who used cannabis, especially daily-users, had shown lower AF. A 
recent longitudinal study conducted in the UK on a representative cohort of pupils showed that high 
childhood academic adjustment at age 11 increased the risk of both occasional and persistent cannabis 
use in late adolescence (19-20 years)75. Our study embraces different countries, and the results are in 
line with those from other studies with non-psychotic people, which indicated that poor school 
performance was a common antecedent of cannabis and other substance use, regardless of IQ, with 
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the odds of dropping out from school increasing with the frequency of use76–79. Similar mechanisms 
are probably implicated in determining AF in patients.  
Finally, we found that patients, but not controls who were cannabis users, particularly daily-users 
had shown better SF than their non-using counterparts. This was even more evident when lifetime 
abusers of other drugs, current cannabis-users, and current tobacco-users were removed from the 
model, and daily-users scored similarly or even better than controls in SF scores.  
In this sensitivity analysis, the confidence intervals in IQ, SF and AF scores increased in patients 
who used cannabis occasionally or daily, compared to never-users; this higher variability is present 
also in control daily users, compared to the other two groups. This may suggest a higher intragroup 
variability in cognition and premorbid functioning or it could, of course, be due to the small numbers, 
which can additionally mask the differences between patients and control daily-users, at least 
regarding the five-point mean-difference in IQ. 
The majority of studies that explored premorbid functioning in psychotic patients selected current 
or recent daily-users and compared them with non-users, revealing worse academic functioning in 
the former23,24,53, conceptually in line with our results on lifetime daily-users. Other studies found no 
association between premorbid function and drug or cannabis abuse80–82, probably because they used 
total PAS mean scores; therefore, inverse results in social and academic factors, related to cannabis-
use, could have nullified each-other. Some authors used a different methodology, focusing on recent 
cannabis-use, and did not find any relationships with premorbid sociability83,84, but better current 
social cognition in recent cannabis-abusers83. This last result was not replicated in a recent study, 
which looked at lifetime cannabis use in relation to current social cognition. . However, as the authors 
state, it is possible that subjects with psychosis and cannabis use, had higher levels of premorbid 
social cognition, responsible for the contact with the substance, which then decreased after the 
diagnosis85. 
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4.3 What can we speculate about premorbid predisposition to psychosis related to cannabis use? 
Cannabis use is probably first self-selected, depending on predisposing factors, such as higher 
early sociability, and later reinforced, in some patients, in a pattern of abuse; this involves the subject 
in a less challenging world (e.g. dropping out from school86–89), that contributes to lower the future 
IQ. This latter does not happen in occasional-users whose IQ is more representative of their premorbid 
cognition14 (see also exploratory analysis on the WAIS subtest – Supplementary Material).  
The early neuropsychological and social deficits (i.e. lower IQ and SF) of non-using patients evoke 
a more ‘classical’ profile of people at-risk to develop psychosis90, in line with the neurodevelopmental 
hypothesis10,91,92. Non-using patients and controls had higher AF before their 16th year, compared 
with cannabis users. While this result is intuitive in controls, it apparently contradicts the expectation 
of a greater impairment in this group of neurodevelopmentally impaired psychotic individuals. 
Previous results showed that premorbid academic adjustment in psychosis is impaired and further 
declines from childhood to late adolescence93,94. These studies reported the most significant 
deterioration between 16 and 18 years (late adolescence), while our PAS measures stop at age 16 
(early adolescence). Interestingly, one of them93 reported a greater premorbid academic decline in 
those with less premorbid social impairment, whom they defined “non-deficit” schizophrenic 
patients, similarly to our results; however, they did not account for cannabis-use. 
 
4.4 Strengths and Limitations  
The EU-GEI study has strengths, such as the large sample size and the use of samples from several 
countries. Even if a prospective cohort study would be able to provide the most robust design for 
establishing causal connections, such a design is problematic, because psychosis is a rare disorder, 
with a large time lag between the occurrence of environmental adversities and the onset.  
The quota sampling strategy to obtain controls with characteristics of each of the study catchment 
areas’ population at risk38 allowed us to have a more representative control sample, as compared to 
previous studies, and suggests that the prevalence of patterns of cannabis use in our controls represent 
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those of the local population35. Sensitivity supplementary analysis revealed the appropriateness of 
this strategy for the outcomes measured, because selection bias was unlikely to explain our findings 
(Supplementary Material).  
The higher IQ in occasional cannabis using controls could be identified thanks to the large sample 
across different countries. People with psychotic disorders might be more likely to recall risk factors95 
and, for example, could recall greater disadvantages in their early life in PAS or to have used drugs 
in CEQ interview. However, the interviews were completed by at least one corroborative source of 
information (e.g. family, clinical notes, other clinicians), and the validity of self-report at the PAS 
has been supported in persons with schizophrenia96. Unlike present use, a history of lifetime use of 
cannabis cannot be assessed by a biological test. Results from our previous study suggest that the 
accuracy of self-reported data on cannabis use is high67. 
Finally, family history for psychosis could be associated with the relationship between cognition 
and cannabis use in patients97. However, no substantial difference in PRS for schizophrenia was found 
in the GAP study between FEP cannabis users and non-users98.  
 
4.5 Implications 
Those patients who use cannabis daily, and only cannabis, in their lifetime were very similar to 
daily-using controls regarding IQ, early sociability and academic adjustment. Thus we can speculate 
that cannabis could have had a role in their psychosis onset, acting as a crucial risk factor35. 
This evidence, coupled with recent confirmations about the strong link between cannabis daily use 
and increased risk for psychosis35, further supports the need to improve primary prevention in the 
general population, and suggests that future studies should look at those factors that make the 
difference between cannabis daily-using subjects that develop psychosis and those who do not. 
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4.6 Conclusions  
The study confirms that patients with first-episode psychosis who used cannabis occasionally have 
higher IQ than never using patients. The findings also demonstrate that both occasional and daily 
cannabis-using patients have better premorbid sociability than non-using patients and that this 
difference is not present among controls. Our findings are compatible with the view that the better 
premorbid social adjustment of cannabis-using patients may have contributed to their early contact 
with the substance, and that cannabis use increases the risk of psychosis in a subgroup of patients 
with less neurodevelopmental vulnerability for psychosis. 
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Figure 1. Standardised scores (estimated marginal means and standard errors) of IQ, Academic 
Factor (AF) and Social Factor (SF) by frequency of cannabis use in patients and controls.  
 
Figure 2. Sensitivity analysis. Standardised scores (estimated marginal means and standard errors) 
of IQ, Academic Factor (AF) and Social Factor (SF) by frequency of cannabis use in patients and 
controls.  
 


